The Financial Opportunity As many of you know, post-operative pain treatment is dominated by opiates, with 95% of patients receiving opiates for pain management. Only one non-opioid, […]
The Financial Opportunity As many of you know, post-operative pain treatment is dominated by opiates, with 95% of patients receiving opiates for pain management. Only one non-opioid, […]
InSitu Biologics’ co-founder and medical adviser Dan Sipple has been featured by his alma mater Des Moines University. Click here to read the article: http://bit.ly/DMUFeature
As of October 19th, our Stock Offering is once again open and accepting investments. Our plan is to close our Regulation A+ Offering for the last time […]
As of October 15, our Stock Offering is temporarily paused. During this pause, we will be taking reservations and encourage prospective investors to reserve shares via the […]
Thank you to LGM Pharma for including InSitu Biologics in a recent Client Feature! We have recently shifted management of our supply chain to LGM Pharma, including […]
InSitu Biologics Announces New Leadership InSitu Biologics today announced that its Board of Directors has appointed Kevin Bassett as President and Chief Executive Officer and member of […]
Tier 4 of the offering has officially closed and we have qualification from the SEC to sell our shares at the price of $8.20 per share. We […]
Special Guest Dr. Jake Hutchins will join us for a wide ranging discussion with Q&A on state of the art in Post-Operative Pain Control. We will also […]
Join us for a veterinarian webcast with Stacie Lipinski, DVM, and Jim Segermark, CEO of InSitu Biologics on Tuesday, June 11th 8:30PM EST / 5:30PM PST. They will discuss […]
InSitu Biologics Corporate from InSitu Biologics